Injectables For HIV? ViiV And Janssen Show The Way
This article was originally published in Scrip
The prospect of using long-acting injections rather than daily pills to suppress HIV has come a step closer with data presented from the LATTE-2 study suggesting that injections of ViiV Healthcare's cabotegravir together with Janssen's rilpivirine have comparable antiviral activity to a standard three-drug oral regimen.
Register for our free email digests: